These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 3042911)

  • 1. Continuous dopaminergic stimulation: state of the art and outlook.
    Horowski R; Marsden CD; Obeso JA
    J Neural Transm Suppl; 1988; 27():249-52. PubMed ID: 3042911
    [No Abstract]   [Full Text] [Related]  

  • 2. [Continuous dopaminergic stimulation in Parkinson disease].
    Obeso JA; Luquin MR; Vaamonde J; Grandas F; Pastor MA; Artieda J; Martínez-Lage JM
    Neurologia; 1987; 2(5):227-34. PubMed ID: 2908545
    [No Abstract]   [Full Text] [Related]  

  • 3. Dopaminergic responsiveness to apomorphine after chronic treatment with subcutaneous lisuride infusion in Parkinson's disease.
    Vaamonde J; Luquin MR; Obeso JA
    Mov Disord; 1990; 5(3):260-2. PubMed ID: 2388647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Continuous subcutaneous lisuride infusions in Parkinson's disease.
    Critchley PH; Grandas Perez F; Quinn NP; Parkes JD; Marsden CD
    J Neural Transm Suppl; 1988; 27():55-60. PubMed ID: 2969953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Subcutaneous apomorphine infusion in the treatment of Parkinson disease].
    Albani C; Zangger I; Fischer G
    Schweiz Rundsch Med Prax; 1992 Aug; 81(35):1011-5. PubMed ID: 1410978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson's disease.
    Stocchi F; Ruggieri S; Vacca L; Olanow CW
    Brain; 2002 Sep; 125(Pt 9):2058-66. PubMed ID: 12183351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients.
    Manson AJ; Turner K; Lees AJ
    Mov Disord; 2002 Nov; 17(6):1235-41. PubMed ID: 12465062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic s.c. lisuride in Parkinson's disease--motor-performance and avoidance of psychiatric side effects.
    Bittkau S; Przuntek H
    J Neural Transm Suppl; 1988; 27():35-54. PubMed ID: 3165438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of apomorphine in Parkinson's disease.
    Stocchi F
    Neurol Sci; 2008 Dec; 29 Suppl 5():S383-6. PubMed ID: 19381769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment of apomorphine infusion adverse effects: subcutaneous nodules and neuropsychiatric complications].
    Giménez de Béjar V; Carballo-Cordero M
    Rev Neurol; 2012; 55 Suppl 1():S25-9. PubMed ID: 23169230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [New types of dopaminergic treatment. The Danish Society of Movement Disorders].
    Karlsborg M; Regeur L
    Ugeskr Laeger; 2006 Mar; 168(12):1209. PubMed ID: 16571300
    [No Abstract]   [Full Text] [Related]  

  • 12. Apomorphine tolerance in Parkinson's disease: lack of a dose effect.
    Gancher ST; Woodward WR; Nutt JG
    Clin Neuropharmacol; 1996 Feb; 19(1):59-64. PubMed ID: 8867518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Continuous dopaminergic stimulation in Parkinson's disease.
    Obeso JA; Luquin MR; Vaamonde J; Grandas F; Martinez Lage JM
    Can J Neurol Sci; 1987 Aug; 14(3 Suppl):488-92. PubMed ID: 3676922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease.
    Colzi A; Turner K; Lees AJ
    J Neurol Neurosurg Psychiatry; 1998 May; 64(5):573-6. PubMed ID: 9598668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subcutaneous lisuride infusion in Parkinson's disease: clinical results using different modes of administration.
    Stocchi F; Ruggieri S; Antonini A; Baronti F; Brughitta G; Bellantuono P; Bravi D; Agnoli A
    J Neural Transm Suppl; 1988; 27():27-33. PubMed ID: 3165437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lisuride infusion pump in Parkinson's disease. A report of two cases.
    Gershanik OS; Scipioni O; García S
    J Neural Transm Suppl; 1988; 27():85-90. PubMed ID: 2969955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The concept of continuous dopaminergic stimulation in the treatment of late stages of Parkinson's disease].
    Titova NV; Katunina EA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(12):105-12. PubMed ID: 24596973
    [No Abstract]   [Full Text] [Related]  

  • 18. [Treatment possibilities in advanced Parkinson's disease].
    Takáts A; Nagy H; Radics P; Tóth A; Tamás G
    Ideggyogy Sz; 2013 Nov; 66(11-12):365-71. PubMed ID: 24555235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TRH test and the continuous dopaminergic stimulation in complicated Parkinson's disease.
    Lestingi L; Bonifati V; Stocchi F; Antonozzi I; Meco G
    Eur Neurol; 1992; 32(2):65-9. PubMed ID: 1563463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of long-term, continuous subcutaneous apomorphine infusions on motor complications in advanced Parkinson's disease.
    Wenning GK; Bösch S; Luginger E; Wagner M; Poewe W
    Adv Neurol; 1999; 80():545-8. PubMed ID: 10410769
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.